Dosimetry of high-dose treatment with 131I in differentiated thyroid cancer -: Evaluation by PET and 124I.

被引：0
|
作者：
Eschmann, SM
Thelen, MH
Reischl, G
Zagar, I
Dohmen, BM
Coenen, HH
Machulla, HJ
Bares, R
机构：
[1] Res Ctr Julich, Julich, Germany
[2] Univ Belgrade, Belgrade, Yugoslavia
[3] Univ Tubingen, Tubingen, Germany
来源：
JOURNAL OF NUCLEAR MEDICINE | 2000年 / 41卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
333
引用
收藏
页码：84P / 84P
页数：1
相关论文
共 50 条
  • [21] Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer
    Sgouros, George
    Hobbs, Robert F.
    Atkins, Francis B.
    Van Nostrand, Douglas
    Ladenson, Paul W.
    Wahl, Richard L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : 41 - 47
  • [22] The diagnostic value of 124I PET compared to 131I imaging in differentiated thyroid cancer: systematic review and meta-analysis.
    Wu, Di
    Heimlich, Layla
    Burman, Kenneth
    Wartofsky, Leonard
    Van Nostrand, Douglas
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [23] Evaluation of response to 131I treatment in children and adolescent with differentiated thyroid carcinoma
    Salvatori, M.
    Spitilli, M. G.
    Pizzoferro, M.
    Maussier, M. L.
    Perotti, G.
    Garganese, M. C.
    Giordano, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S342 - S343
  • [24] 124I PET/CT in the pretherapeutic staging of differentiated thyroid carcinoma: comparison with posttherapy 131I SPECT/CT
    Cecile de Pont
    Servais Halders
    Jan Bucerius
    Felix Mottaghy
    Boudewijn Brans
    European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40 : 693 - 700
  • [25] 124I PET/CT in the pretherapeutic staging of differentiated thyroid carcinoma: comparison with posttherapy 131I SPECT/CT
    de Pont, Cecile
    Halders, Servais
    Bucerius, Jan
    Mottaghy, Felix
    Brans, Boudewijn
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (05) : 693 - 700
  • [26] Factors influencing the dosimetry and the therapeutic outcome of 131I therapy of differentiated thyroid cancer (DTC).
    Behr, TM
    Béhé, MP
    Gratz, S
    Hüfner, M
    Becker, W
    JOURNAL OF NUCLEAR MEDICINE, 2001, 42 (05) : 242P - 242P
  • [27] Previsional Red Marrow Dosimetry in Differentiated Thyroid Cancer with I131 and I124: is a Reliable Value?
    Rossi, G.
    Camarda, M.
    D'Avenia, P.
    Di Nicola, E.
    Montani, L.
    Bartolozzi, C.
    Dente, A.
    Gasparrini, N.
    Brianzoni, E.
    Fattori, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S127 - S127
  • [28] Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software
    Kolbert, Katherine S.
    Pentlow, Keith S.
    Pearson, Joel R.
    Sheikh, Arif
    Finn, Ronald D.
    Humm, John L.
    Larson, Steven M.
    JOURNAL OF NUCLEAR MEDICINE, 2007, 48 (01) : 143 - 149
  • [29] Evaluation of 124I PET/CT and 124I PET/MRI in the management of patients with differentiated thyroid cancer
    Dercle, Laurent
    Deandreis, Desiree
    Terroir, Marie
    Leboulleux, Sophie
    Lumbroso, Jean
    Schlumberger, Martin
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (06) : 1006 - 1010
  • [30] Evaluation of 124I PET/CT and 124I PET/MRI in the management of patients with differentiated thyroid cancer
    Laurent Dercle
    Désirée Deandreis
    Marie Terroir
    Sophie Leboulleux
    Jean Lumbroso
    Martin Schlumberger
    European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43 : 1006 - 1010
12345